Filtered By:
Management: WHO
Countries: USA Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 45 results found since Jan 2013.
Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk
Partnership combines Roche ’s proven track record of successfully developing and launching innovative medicines worldwide withAlnylam ’s leadership in RNAi therapeuticsZilebesiran, a Phase 2 RNAi therapeutic, has best-in-disease potential for patients with hypertension at high risk of cardiovascular morbidity and mortality, by robustly and durably lowering blood pressureHypertension, the leading cause of cardiovascular disease, affects more than 1.2 billion adults worldwide. While several therapies exist, a significant unmet need, especially for high risk patients, remains.1Basel, 24 July 2023 - Roche (SIX: RO, ROG; OT...
Source: Roche Media News - July 24, 2023 Category: Pharmaceuticals Source Type: news
What Sub-Saharan African Nations Can Teach the U.S. About Black Maternal Health
While poor maternal outcomes among Black women in the U.S. is not new, improving it is imperative. U.S. policymakers can look to sub-Saharan Africa for guidance on reversing this trend. Credit: Ernest Ankomah/IPSBy Ifeanyi NsoforABUJA, Jun 2 2023 (IPS) New research shows that Black mothers in the United States disproportionately live in counties with higher maternal vulnerability and face greater risk of preterm death for the fetus, greater risk of low birth weight for a baby, and a higher number of maternal deaths.
While poor maternal outcomes among Black women in the U.S. is not new, improving it is imperative. U.S. poli...
Source: IPS Inter Press Service - Health - June 2, 2023 Category: International Medicine & Public Health Authors: Ifeanyi Nsofor Tags: Africa Gender Headlines Health Inequality North America Poverty & SDGs Maternal Health Source Type: news
Nanocarriers and Diabetes: New Vistas and the way ahead
Curr Pharm Biotechnol. 2022 Dec 27. doi: 10.2174/1389201024666221227140728. Online ahead of print.ABSTRACTWorld Health Organization has reported an estimated 1.5 million deaths directly due to diabetes in 2019. Center for Disease Control and Prevention, in its National Diabetes Statistics Report, 2020, says that 1 in 10 United States residents has diabetes. This rapid progression of diabetes is noteworthy despite significant advances in the field of antidiabetic medicine. The critical challenges in treatment are dyslipidemia, hyperinsulinemia, and hyperglycemia. The latest research has also linked diabetes to carcinogenesi...
Source: Current Pharmaceutical Biotechnology - December 29, 2022 Category: Biotechnology Authors: Pankaj V Dixit Dinesh K Mishra Sanjay Sharma Rupesh K Gautam Source Type: research
The final puff: Can New Zealand quit smoking for good?
Smoking kills. Ayesha Verrall has seen it up close. As a young resident physician in New Zealand’s public hospitals in the 2000s, Verrall watched smokers come into the emergency ward every night, struggling to breathe with their damaged lungs. Later, as an infectious disease specialist, she saw how smoking exacerbated illness in individuals diagnosed with tuberculosis and HIV/AIDS. She would tell them: “The best thing you can do to promote your health, other than take the pills, is to quit smoking.”
Verrall is still urging citizens to give up cigarettes—no longer just one by one, but by the thousands. As New...
Source: ScienceNOW - December 9, 2022 Category: Science Source Type: news
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
COVID-19 meets neurointervention on the pages of JNIS
As 2019 came to a close, a novel B-coronavirus, labeled by the World Health Organization as COVID-19, was noted to be spreading in China.1 The COVID-19 virus is an enveloped single-strand, positive-sense RNA, which means that the virus can use its RNA as the template from which to create proteins needed for propagation and, ultimately, spread. The name coronavirus refers to the characteristic crown-like appearance of these viruses that is seen on electron microscopy. By spring 2020, COVID-19 was spreading rapidly throughout the United States and Europe, and neurointerventionalists soon found themselves on the frontline.2 T...
Source: Journal of NeuroInterventional Surgery - September 15, 2021 Category: Neurosurgery Authors: Milburn, J. M., Regenhardt, R. W., Fiehler, J., Fargen, K. M., Hirsch, J. A. Tags: COVID-19 Commentary Source Type: research
Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
The importance of extended working hours for work-related injuries
Discussion of Reduction Strategies and Behavioral Responses from a North American Perspective. Euro J Trans Infra Res. 2002;2(4).
21. POPM.gov [internet] Policy, Data, Oversight. Available from: https://www.opm.gov/policy-data-oversight/pay-leave/work-sched ules/fact-sheets/alternative-work-schedules-compressed-work-schedules/. Accessed June 30, 2021.
22. Kivimäki M, Nyberg ST, Batty GD, Fransson EI, Heikkilä K, Alfredsson L, et al. Job strain as a risk factor for coronary heart disease: a collaborative meta-analysis of individual participant data. Lancet. 2012;380(9852):1491-7. https://doi.org/10.1016/S0140-6736(12)60...
Source: Scandinavian Journal of Work, Environment and Health - August 11, 2021 Category: Occupational Health Tags: Editorial Source Type: research
Roche launches new ways to use their cardiovascular tests empowering clinicians to improve diagnosis and treatment of millions of people
Basel, 28 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced a series of five new intended uses for two key cardiac biomarkers using the Elecsys ® technology: high sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP). These gold standard biomarkers³ have proven to be successful in supporting cardiovascular disease management and can help clinicians diagnose heart attacks⁴ (cTnT-hs) and bett er manage heart failure⁵ (NT-proBNP). Roche ' s introduction of five new intended uses for these existing, globally accepted diagnostic solutions means more people could benef...
Source: Roche Media News - April 28, 2021 Category: Pharmaceuticals Source Type: news
International Nursing Collaboration to Establish the Philippine Quit Line: Using a Conceptual Model for Partnership and Sustainability in Global Health
Tobacco use remains the single most preventable cause of death and disability worldwide. In the Philippines, 28.3% of the people are current tobacco smokers, which is one of the highest smoking rates in Asia. The World Health Organization estimates that 10 Filipinos die every day from cancer, stroke, and lung and heart disease caused by cigarette smoke and approximately 24 million Filipinos are exposed to secondhand smoke in the home. Although there are quit lines in all 50 U.S. states and territories, there was no access to this smoking cessation program in the Philippines before the initiation of the international collab...
Source: Journal of Addictions Nursing - January 1, 2021 Category: Addiction Tags: Original Articles Source Type: research
